Company intelligence / Profile preview

CellProthera

Mulhouse, Grand Est, Francecellprothera.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has conducted successful proof of principle studies with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct, showing an excellent safety profile with outstanding clinical benefits. As of 2016, they were completing Phase I/IIb clinical trials in Europe and preparing for Phase III trials in Europe and North America[2].

Therapeutic areas: Cardiovascular
Modalities: Cell therapystem cell therapy
Industry: Biotech

Drug pipeline

1 asset

ProtheraCytes

Unknown

Beyond the preview

Go deeper on CellProthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellProthera.

Explore the full profile